Drug Trial Radar · NCT02193867
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
Last checked: Nov 20, 2026Latest source record: Nov 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Jun 6, 2014
Primary completion
Oct 30, 2018
Study completion Oct 30, 2018
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 18, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 8 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
Conditions
- Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase AlfaDrug
Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)Time frame: Screening through Month 37
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Kuopio, Finland
Site not named
Naples, Italy
Site not named
Birmingham, United Kingdom
Site not named
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.